It was subsequently shown that the ability to eliminate BRCA1/2‐deficient cells and tumours is also a feature of the G4 ligand CX‐5461 (Xu et al, 2017), which is currently evaluated in clinical trials in patients with DNA repair defects (NCT02719977 ClinicalTrials.gov). This evidence concerns the gene BRCA1 and neoplasm.